Venetoclax is a medicine used in this study to help children and young people with a type of blood cancer called Acute Myeloid Leukemia (AML). Sometimes, this cancer comes back even after treatment. This study is for those who cannot use certain other medicines. Venetoclax aims to help by making cancer cells die. It is given with strong chemotherapy medicines like fludarabine, cytarabine, and gemtuzumab ozogamicin. The study allows up to two cycles of treatment before a possible stem cell transplant. If the treatment helps but a transplant isn't possible, some participants may continue with different medicines.

• Participants need to visit the hospital for treatment and check-ups.
• You may join if you are between 29 days and 21 years old, and meet certain health conditions.
• It's important to understand the risks and benefits before joining.

To be part of the study, participants must have certain health conditions and cannot have others, like Down syndrome or active infections. They should not be pregnant or breastfeeding and must agree to use birth control if needed. Always talk to your doctor to understand if this study is right for you.